Autoimmune encephalitis
diseaseOn this page
Summary
Autoimmune encephalitis (MONDO:0020640) is a disease and 57 clinical trials. Top therapeutic interventions include rituximab, efgartigimod alfa, and human immunoglobulin g. A subtype of autoimmune disorder of central nervous system — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 57
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | autoimmune encephalitis |
| Mondo ID | MONDO:0020640 |
| Orphanet | 622014 |
| ICD-11 | 241281019 |
| NCIT | C122414 |
| SNOMED CT | 95643007 |
| UMLS | C5671289 |
| MedGen | 1804547 |
| GARD | 0011979 |
| Is cancer (heuristic) | no |
Also known as: autoimmune encephalitis
Disease family
This is a subtype of autoimmune disorder of central nervous system. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › autoimmune disorder of central nervous system › autoimmune encephalitis
Related subtypes (7): multiple sclerosis, Miller Fisher syndrome, autoimmune encephalopathy with parasomnia and obstructive sleep apnea, lymphocytic hypophysitis, autoimmune optic neuritis, central nervous system lupus, autoimmune epilepsy
Subtypes (2): steroid-responsive encephalopathy associated with autoimmune thyroiditis, autoimmune limbic encephalitis
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 57.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 38 |
| PHASE2 | 9 |
| PHASE1 | 4 |
| EARLY_PHASE1 | 3 |
| PHASE4 | 1 |
| PHASE3 | 1 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03004209 | PHASE4 | WITHDRAWN | Effect of Erythropoietin in Refractory Autoimmune Encephalitis Patients |
| NCT05177939 | PHASE3 | UNKNOWN | Phase III Clinical Study of NPB-01 in Patients With Autoimmune Encephalitis |
| NCT03194815 | PHASE2 | ACTIVE_NOT_RECRUITING | IVIG and Rituximab in Antibody-associated Psychosis - SINAPPS2 |
| NCT03993262 | PHASE2 | RECRUITING | Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis |
| NCT04372615 | PHASE2 | RECRUITING | The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis |
| NCT07093333 | PHASE2 | RECRUITING | A Study in Participants With Anti-NMDAR Encephalitis and Anti-NMDAR Autoantibody-Associated Psychiatric Disease |
| NCT07131683 | PHASE1/PHASE2 | NOT_YET_RECRUITING | hUC-MSC-Exo Therapy for Autoimmune Encephalitis |
| NCT07488117 | PHASE2 | RECRUITING | Is [18F]-DPA-714 PET a Good Marker of Neuroinflammation in Autoimmune Encephalitis? |
| NCT07583641 | PHASE2 | NOT_YET_RECRUITING | A Study to Learn About How Well the Medicine Efgartigimod Works to Treat Autoimmune Encephalitis In Children 12 Years or Older and Adults |
| NCT03835728 | PHASE2 | TERMINATED | Efficacy of Ocrelizumab in Autoimmune Encephalitis |
| NCT04175522 | PHASE2 | COMPLETED | Safety and Efficacy of IGIV 10% in Patients With Autoimmune Encephalitis: |
| NCT06033846 | PHASE2 | COMPLETED | Efficacy and Safety of Adjunctive Minocycline in the Treatment of Autoimmune Encephalitis |
| NCT07341828 | PHASE1 | NOT_YET_RECRUITING | A Study of C-CAR168 in the Treatment of Central Nervous System Autoimmune Diseases Refractory to Standard Therapy |
| NCT07526493 | PHASE1 | RECRUITING | Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases. |
| NCT06575153 | PHASE1 | COMPLETED | Phase 1 Study of ART5803 in Healthy Participants |
| NCT06753955 | PHASE1 | COMPLETED | Phase 1 Study of ART5803 Safety and PK After IVIG in Healthy Participants |
| NCT04561557 | EARLY_PHASE1 | RECRUITING | Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System |
| NCT06939166 | EARLY_PHASE1 | RECRUITING | Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD19/BCMA） in Patients With r/r Neurological Autoimmune Diseases |
| NCT07337785 | EARLY_PHASE1 | RECRUITING | CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases |
| NCT04806620 | Not specified | RECRUITING | Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research |
| NCT05198661 | Not specified | RECRUITING | Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis Collection |
| NCT05728931 | Not specified | ACTIVE_NOT_RECRUITING | New Biomarkers in Auto-immune Encephalitis and Neurological Paraneoplastic Syndromes |
| NCT05772611 | Not specified | RECRUITING | Characterization of Immune-response in Autoimmune Encephalitis and Paraneoplastic Neurological Syndromes |
| NCT06019975 | Not specified | RECRUITING | FDG-PET in the Diagnosis of Autoimmune Encephalitis |
| NCT06079294 | Not specified | RECRUITING | Impact of Confirmed Autoimmune Encephalitis on Brain Glucose Metabolism |
| NCT06173076 | Not specified | RECRUITING | A Prospective Study to Evaluate Clinical Outcomes in Anti-LGI1 Encephalitis |
| NCT06432803 | Not specified | ACTIVE_NOT_RECRUITING | Metabolic Imaging for Diagnosis and Prognostication of Autoimmune encephalitiS |
| NCT06456736 | Not specified | NOT_YET_RECRUITING | Clinical Features and Prognostic Markers in Adult Patients With AE Requiring ICU Treatment |
| NCT06502015 | Not specified | RECRUITING | Biomarkers in Autoimmune Disease of Nervous System |
| NCT06584045 | Not specified | RECRUITING | Efficacy and Safety of Calculus Bovis Sativus (CBS) for Adult Encephalitis (CBSinEncephalitis) |
| NCT06697678 | Not specified | NOT_YET_RECRUITING | Risk Prediction Model for Severe Autoimmune Encephalitis |
| NCT06760091 | Not specified | NOT_YET_RECRUITING | A Multicentric Cohort of Autoimmune Encephalitis |
| NCT07145502 | Not specified | ACTIVE_NOT_RECRUITING | Monitoring of Outcomes of Cellular and Exosome-based Therapies in Autoinflammatory and Post-infectious Neuroinflammatory Syndromes |
| NCT07333196 | Not specified | NOT_YET_RECRUITING | Tongji NADs Cohort |
| NCT07477015 | Not specified | RECRUITING | Study of Pathogenic Mechanisms and Identification of Novel Autoantibodies in Autoimmune Encephalitis |
| NCT02905136 | Not specified | COMPLETED | Mechanisms of Auto-immune Encephalitis |
| NCT03530462 | Not specified | COMPLETED | To Explore Cognitive Neural Mechanism of Autoimmune Encephalitis by Using Neuropsychological Tests and Multi-modal MRI |
| NCT03542279 | Not specified | COMPLETED | CPI Combination Therapy for Autoimmune Encephalitis |
| NCT03872284 | Not specified | COMPLETED | Neuro-ophthalmology and Autoimmune Encephalitis (NODE) |
| NCT03957616 | Not specified | UNKNOWN | Incidence of Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| RITUXIMAB | 4 | 2 |
| EFGARTIGIMOD ALFA | 4 | 1 |
| HUMAN IMMUNOGLOBULIN G | 4 | 1 |
| INEBILIZUMAB | 4 | 1 |
| LACOSAMIDE | 4 | 1 |
| OCRELIZUMAB | 4 | 1 |